Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Kielce – page 10

187 clinical trials in Kielce, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Kielce at a glance
187
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

187 trials in Kielce

Open in trial search

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
  • Sponsor:Janssen Cilag International

Obesity

Not recruiting

Comparing the efficacy and safety of KAI-9531 and semaglutide in people living with obesity who do not have diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Relapsing multiple sclerosis

Not recruiting

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Major depression

Not recruiting

Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Citalopram
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Vitiligo

Not recruiting

A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Atrial fibrillation+5

Not recruiting

Study of Allopurinol to Reduce Cardiovascular Events in High-Risk Patients with Heart Disease and Long-COVID Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Agencja Badań Medycznych

Chronic lymphocytic leukaemia

Not recruiting

Study on the Effectiveness of Venetoclax and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Polish Adult Leukemia Group

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Kielce

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and lymphoma treatments. Studies evaluate novel drug combinations and targeted therapies for improved patient outcomes.

  • Blood cancers and solid tumors
  • Targeted therapy approaches
  • Combination treatment strategies

Advanced research includes studies on prostate cancer and neuroendocrine tumors using cutting-edge therapeutic approaches.

02 Neurological Disorders

Groundbreaking research in multiple sclerosis and Alzheimer's disease. Trials evaluate new treatments for both relapsing forms of MS and psychosis associated with Alzheimer's.

  • Disease-modifying therapies
  • Neurodegeneration treatments
  • Symptom management

Focus on developing innovative therapeutic solutions for complex neurological conditions.

03 Cardiovascular and Metabolic Studies

Comprehensive research addressing hypertension, cardiovascular disease, and metabolic disorders. Studies investigate preventive approaches and novel treatment combinations.

  • Heart failure prevention
  • Blood pressure management
  • Metabolic health

Innovative trials exploring new therapeutic strategies for cardiovascular risk reduction.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.